Showing 1781-1790 of 2739 results for "".
The Benefits of Private Practice: A Q&A with Joel Schlessinger, MD, FAAD
https://practicaldermatology.com/issues/september-2025/the-benefits-of-private-practice-a-qa-with-joel-schlessinger-md-faad/37630/While selling to and working for private equity–backed platforms may have its perks, many long-time private practitioners warn that the advantages of private practice are often not fully appreciated until it is too late. Practical Dermatology Chief Cosmetic Surgery Editor Emeritus Joel Schlessinger,Melanoma and the Predictive Value of Nevi: Unexpected Findings?
https://practicaldermatology.com/topics/practice-management/melanoma-and-the-predictive-value-of-nevi-unexpected-findings/20936/A new analysis shows that the association between nevi and melanoma is complex.DermWireTV: Qwo Approved, Assessing Resident Anxiety
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-qwo-approved-assessing-resident-anxiety/19830/FDA has approved Qwo (collagenase clostridium histolyticum-aaes) from Endo, the first injectable treatment approved for moderate to severe cellulite in the buttocks of adult women. A recent survey offers perspective on anxiety among third-year dermatology residents in light of the COVID crisis. AlleDermWire TV: Merz Reorganizes; Amzeeq Approved; Restoration Merges with Venus Concept
https://practicaldermatology.com/videos/dermwire-tv/dermwire-tv-merz-reorganizes-amzeeq-approved-restoration-merges-with-venus-concept/19694/Bob Rhatigan, newly appointed Global Chief Executive Officer of Merz Aesthetics, speaks about Merz reorganization. Amzeeq topical foam (Foamix Pharmaceuticals) approved for inflammatory, non-nodular, moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older. FDExtended Half-Life and Long-Acting Biologics for the Treatment of Psoriasis
https://practicaldermatology.com/topics/psoriasis/extended-half-life-and-long-acting-biologics-for-the-treatment-of-psoriasis/60876/Explore the biologic rationale, emerging clinical candidates, and key unanswered questions surrounding extended half-life therapies for psoriatic disease.A Novel Topical Cream to Reduce Bruising
https://practicaldermatology.com/topics/general-topics/a-novel-topical-cream-to-reduce-bruising/21476/Although options to treat bruising have been limited, a new cream may be especially useful for older patients.Why Has the Market Gone Up When Economic News Looks Grim?
https://practicaldermatology.com/topics/practice-management/why-has-the-market-gone-up-when-economic-news-looks-grim/23314/A look at seven factors affecting the market.Melanoma in Skin of Color: More to Learn
https://practicaldermatology.com/topics/skin-cancer-photoprotection/melanoma-in-skin-of-color-more-to-learn/23486/With evidence showing that cumulative UV exposure is not strongly correlated with melanoma risk in patients with skin of color, dermatologists must re-consider their messaging.Innovation Station
https://practicaldermatology.com/topics/practice-management/innovation-station/20751/CES 2017 unveils a host of digital health tools.Rituximab-induced Serum Sickness in Pemphigus Vulgaris: A Case Report and Literature Review
https://practicaldermatology.com/youngmd-connect/resident-resource-center/rituximab-induced-serum-sickness-in-pemphigus-vulgaris-a-case-report-and-literature-review/20808/